Details for New Drug Application (NDA): 202313
✉ Email this page to a colleague
The generic ingredient in ADENOSINE is adenosine. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.
Summary for 202313
| Tradename: | ADENOSINE |
| Applicant: | Avet Lifesciences |
| Ingredient: | adenosine |
| Patents: | 0 |
Pharmacology for NDA: 202313
| Mechanism of Action | Adenosine Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 202313
Suppliers and Packaging for NDA: 202313
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ADENOSINE | adenosine | SOLUTION;INTRAVENOUS | 202313 | ANDA | NorthStar Rx LLC | 16714-556 | 16714-556-01 | 1 VIAL in 1 CARTON (16714-556-01) / 20 mL in 1 VIAL |
| ADENOSINE | adenosine | SOLUTION;INTRAVENOUS | 202313 | ANDA | NorthStar Rx LLC | 16714-997 | 16714-997-01 | 1 VIAL in 1 CARTON (16714-997-01) / 30 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 60MG/20ML (3MG/ML) | ||||
| Approval Date: | Sep 15, 2014 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 90MG/30ML (3MG/ML) | ||||
| Approval Date: | Sep 15, 2014 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
